What is Lifesci Capital’s Forecast for SLNO Q1 Earnings?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Equities research analysts at Lifesci Capital lowered their Q1 2025 earnings per share estimates for Soleno Therapeutics in a report released on Thursday, March 27th. Lifesci Capital analyst M. Belghiti now anticipates that the company will earn ($1.46) per share for the quarter, down from their prior estimate of ($1.43). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.32 EPS and FY2026 earnings at ($0.47) EPS.

Several other equities analysts also recently commented on the company. Laidlaw increased their price target on Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Soleno Therapeutics in a research note on Monday, March 3rd. Robert W. Baird boosted their target price on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday. Stifel Nicolaus raised their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a research report on Friday. Finally, Cantor Fitzgerald boosted their price objective on Soleno Therapeutics from $67.00 to $123.00 and gave the stock an “overweight” rating in a research report on Thursday. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Soleno Therapeutics currently has a consensus rating of “Buy” and an average target price of $94.57.

Soleno Therapeutics Stock Performance

SLNO opened at $71.99 on Monday. The stock has a 50-day moving average of $48.94 and a 200-day moving average of $50.08. Soleno Therapeutics has a 52-week low of $36.61 and a 52-week high of $73.97. The company has a market cap of $3.30 billion, a PE ratio of -21.68 and a beta of -1.70.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

Insider Buying and Selling

In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 10,937 shares of Soleno Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the sale, the chief executive officer now owns 708,616 shares in the company, valued at $32,178,252.56. The trade was a 1.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kristen Yen sold 2,340 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total transaction of $108,061.20. Following the completion of the transaction, the insider now owns 76,605 shares of the company’s stock, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,360 shares of company stock valued at $790,119 over the last three months. 12.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds have recently modified their holdings of SLNO. Janus Henderson Group PLC boosted its stake in Soleno Therapeutics by 27.1% in the 4th quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company’s stock valued at $233,130,000 after buying an additional 1,107,166 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Soleno Therapeutics by 20.1% in the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company’s stock valued at $176,607,000 after purchasing an additional 658,518 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Soleno Therapeutics by 15.8% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company’s stock worth $113,499,000 after purchasing an additional 344,000 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Soleno Therapeutics by 19.2% during the 4th quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company’s stock worth $84,710,000 after purchasing an additional 303,806 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Soleno Therapeutics by 24.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company’s stock valued at $73,301,000 after purchasing an additional 321,223 shares during the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.